Journal article icon

Journal article

Quinone oxidoreductase-2-mediated prodrug cancer therapy.

Abstract:

DNA-damaging agents are widely used in cancer treatment despite their lack of tumor specificity. Human NQO2 (quinone oxidoreductase-2) is an atypical oxidoreductase because no endogenous electron donor has been identified to date. The enzyme converts CB1954 [5-(aziridin-1-yl)-2,4-dinitrobenzamide], in the presence of the synthetic nicotinamide cofactor analog EP0152R, to a cytotoxic bifunctional alkylating agent. NQO2 activity in hepatocellular tumor tissue is higher than that in other cancer...

Expand abstract
Publication status:
Published

Actions


Access Document


Authors


Middleton, MR More by this author
Cattell, E More by this author
Oppermann, U More by this author
More by this author
Institution:
University of Oxford
Department:
Oxford, MSD, Oncology
Expand authors...
Journal:
Science translational medicine
Volume:
2
Issue:
40
Pages:
40ra50
Publication date:
2010-07-05
DOI:
EISSN:
1946-6242
ISSN:
1946-6234
URN:
uuid:360a29ed-28c0-4d52-be87-877eb01745e7
Source identifiers:
108380
Local pid:
pubs:108380

Terms of use


Metrics



If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP